Zobrazeno 71 - 80
of 104
pro vyhledávání: '"Katy K. Tsai"'
Publikováno v:
Journal of Clinical Oncology. 35:e21593-e21593
e21593 Background: Tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) have resulted in durable response for many cancer patients. The impact of these agents on future fertility are not well described, and patients are often commi
Publikováno v:
Journal of Clinical Oncology. 35:e21594-e21594
e21594 Background: Survivorship concerns–including sexual function–move increasingly to the foreground in cancer patient care as systemic therapies improve response and survival. Patients are often committed to long-term treatment with tyrosine k
Autor:
Zeynep Eroglu, Sophie Feng, John J. Park, Katy K. Tsai, Alpaslan Özgün, Victoria Atkinson, Alexander M. Menzies, Jennifer L. McQuade, Andrew P.D. Henderson, Shahneen Sandhu, Georgina V. Long, Ryan J. Sullivan, Lavinia Spain, Matteo S. Carlino, Jess Louise Smith, Justine V. Cohen, James Larkin, Douglas B. Johnson, Margarida Mut Lioret
Publikováno v:
Journal of Clinical Oncology. 35:e21641-e21641
e21641 Background: The anti-PD1 antibodies (PD1) pembrolizumab and nivolumab are now FDA-approved in multiple malignancies. With increased use, rarer immune-related adverse events (irAEs) not well characterized in clinical trials are being identified
Autor:
Hala T. Borno, Katy K. Tsai, Won Kim, Rahul Aggarwal, Emily K. Bergsland, Pelin Cinar, Brook Calton, Reena Mahajan, Melisa L. Wong, Kara Bischoff
Publikováno v:
Journal of Clinical Oncology. 35:63-63
63 Background: Advance care planning (ACP) is an important component of high quality care for cancer patients. A measurable and early step in the ACP process is for patients to identify a surrogate decision maker and document this information in the
Autor:
Carmen Ballesteros-Merino, Erica Browning, Adil Daud, Mai H. Le, Jean S. Campbell, Chris Twitty, Robert H. Pierce, Mary Dwyer, Bernard A. Fox, Carlo Bifulco, Alain Algazi, Sharron Gargosky, Kathryn Toshimi Takamura, Katy K. Tsai, Reneta Talia, Robert H.I. Andtbacka, Amy Li, Michael Rosenblum
Publikováno v:
Journal of Clinical Oncology. 35:78-78
78 Background: Recent publications support the emergence of predictive biomarkers for pembrolizomab in melanoma based on the expression of PD-L1 in the tumor microenvironment (Daud 2016a) or the frequency of PD-1hiCTLA-4hi on CD8+ TIL (Daud 2016b) wh
Autor:
Mary Dwyer, Mai H. Le, Tu Diep, Kathryn Toshimi Takamura, Lawrence Fong, Katy K. Tsai, Lawrence Chen, Chris Twitty, Adil Daud, Alain Algazi, Robert H. Pierce, Samantha K. Greaney
Publikováno v:
Cancer Research. 76:CT134-CT134
Background: Intratumoral electroporation of plasmid IL-12 (IT-pIL12-EP) induces tumor infiltrating lymphocytes (TILs) and anti-tumor immunity in melanoma as described in previous Phase 1 and 2 clinical trials. PD-1 and PD-L1 antibodies induce durable
Autor:
Mariela L. Pauli, Adil Daud, Priscila Munoz Sandoval, Katy K. Tsai, Alain Algazi, Michael Alvarado, Michael Rosenblum, Kimberly Loo
Publikováno v:
Journal of Clinical Oncology. 34:9520-9520
9520Background: The identification of a robust biomarker to determine potential responses to checkpoint mono- or combination therapy is critical in order to stratify patients and rationally select ...
Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM)
Autor:
Richard D. Carvajal, Katy K. Tsai, Alexander N. Shoushtari, Bartosz Chmielowski, Zeynep Eroglu, Ryan J. Sullivan, Adil Daud, Michael A. Postow, Jimmy Hwang, Rodrigo Ramella Munhoz, Patrick A. Ott, Josep M. Piulats, Jeffrey A. Sosman, Alain Algazi, Douglas B. Johnson, Jeffrey S. Weber
Publikováno v:
Journal of Clinical Oncology. 34:9507-9507
9507Background: PD-1 pathway inhibitors have shown significant activity in the treatment of advanced cutaneous melanoma. Their role in UM has not yet been well characterized. UM has molecular, path...
Autor:
Adi Nosrati, Omid Hamid, Simone M. Goldinger, Adil Daud, Alain Algazi, Reinhard Dummer, Paul C. Tumeh, Mitchell P. Levesque, Kimberly Loo, Katy K. Tsai
Publikováno v:
Journal of Clinical Oncology. 34:9514-9514
9514Background: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to Anti-PD-1 in advanced melanoma...
Autor:
Adil Daud, Luca Facchetti, Alain Algazi, Miguel Hernandez Pampaloni, Kimberly Loo, Susana Ortiz-Urda, Katy K. Tsai, Lorenzo Nardo
Publikováno v:
Journal of Clinical Oncology. 34:11572-11572
11572Background: Development of biomarkers to evaluate prolonged systemic treatment response is crucial for optimizing individual checkpoint inhibitor therapies. Glucose consumption rates assessed ...